SCM
PRAX icon

Superstring Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Superstring Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-40,119
Closed -$2.45M – 52
2024
Q1 		$2.45M Buy
+40,119
New +$1.8M 1.62% 19

Other funds holding PRAX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Superstring Capital Management's PRAX Position: Q2 2024 in Review

Superstring Capital Management sold out of Praxis Precision Medicines (PRAX) in Q2 2024, closing a stake of 40,119 shares — an estimated $2.45M sold.

Superstring Capital Management first reported a position in PRAX in Q1 2024 and held it in 1 quarter. The position peaked at $2.45M in Q1 2024. 113 funds tracked by Wall St. Rank hold PRAX as of Q2 2024.

  • Superstring Capital Management reported no remaining Praxis Precision Medicines position as of Q2 2024 after selling out during the quarter.
  • Superstring Capital Management sold 40,119 Praxis Precision Medicines shares in Q2 2024, an estimated $2.45M.
  • Superstring Capital Management first reported a position in Praxis Precision Medicines in Q1 2024 and held it in 1 quarter.
  • Superstring Capital Management's Praxis Precision Medicines position peaked at $2.45M in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2024.

Based on Superstring Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.